Experts warn about temporary 'spikes' caused by 'dengue vaccine'

Image
ANI Washington
Last Updated : Sep 08 2014 | 1:15 PM IST

Scientists have warned that dengue vaccines could cause short-term but major spikes in the years after they are first used.

Jan Medlock, an assistant professor at Oregon State University said that their analysis suggested that if they developed and widely used a vaccine for dengue fever, there might later be spikes in the incidence of the disease that were two to three times higher than its normal level.

The research was done by experts at the OSU College of Veterinary Medicine and Clemson University, both of which supported the studies. Scientists used mathematical modeling to examine the quirks of infectious disease transmission that may lead to this quandary. The work was specific to dengue fever, but might also be relevant to other diseases for which vaccines are being sought, such as malaria, and in which the level of protection is less than total.

According to the researchers, the beginning of a vaccination program would slow the numbers of children getting the disease, for a while. But it's expected that a dengue vaccine would not provide total protection against infection. Then, during a period when naturally fluctuating mosquito populations reach an unusually high level, a disproportionate number of children, who were still vulnerable to infection and have never had the disease, would become infected in a short period.

This could cause loss of faith in the vaccination program among the public or policy makers who have never seen such high levels of the disease, stretch the capabilities of health care facilities and workers to care for the sick, and in a worst-case scenario lead people to avoid the vaccine, researchers said. Some short-term spikes could even be as high as seven times the average rate, they said.

A possible way to deal with this phenomenon, scientists said, was literally to vaccinate fewer people. That would cause higher number of people to get the disease in the long run, but reduce the intensity of the spikes and the associated demands on a health care system.

The study is published in Epidemiology and Infection.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 08 2014 | 1:00 PM IST

Next Story